VIRUSLARGA QARSHI YANGI AVLOD DORI VOSITALAR.
DOI:
https://doi.org/10.37547/Keywords:
virus, antiviral dori vositalari, interferon, mRNK, nanodori tizimi, farmakodinamika, immunomodulyator, proteaza inhibitörlari, nukleozid analoglari, farmatsevtik biotexnologiya.Abstract
Ushbu ilmiy maqolada viruslarga qarshi dori vositalarining rivojlanish bosqichlari, ularning farmakodinamik va farmakokinetik xususiyatlari, shuningdek, yangi avlod antiviral preparatlarning molekulyar ta’sir mexanizmlari yoritilgan. Tadqiqotda nanodori tizimlari, mRNK asosidagi dori shakllari, proteaza inhibitörlari, polimeraza blokatorlari va immunomodulyatorlarning zamonaviy farmatsevtik amaliyotdagi o‘rni ilmiy tahlil qilinadi. Shuningdek, COVID-19 pandemiyasi sharoitida antiviral terapiyaning o‘zgarishi, yangi dori vositalarining samaradorligini baholash metodlari va istiqbolli yo‘nalishlar haqida batafsil fikr yuritilgan.
Downloads
References
1. Karimov Sh. va boshqalar. Farmatsevtik biotexnologiya asoslari. Toshkent: Fan, 2021.
2. Abdullayeva M., Niyozov A. Virusologiya va immunologiya asoslari. Toshkent, 2020.
3. G‘ulomova D. Nanotibbiyot va farmatsiya istiqbollari. Toshkent: Tibbiyot nashriyoti, 2022.
4. O‘zbekiston Respublikasi sog‘liqni saqlash vazirligi. COVID-19 davolash protokoli. Toshkent, 2021.
5. Rahimova N. Antiviral vositalarning farmakologiyasi. Toshkent, 2023.
6. World Health Organization. Antiviral drug development overview, 2022.
7. FDA Annual Report on Antiviral Research, 2023.
8. Alimova M. Farmatsevtik bioetika va zamonaviy dori yaratish muammolari. Toshkent, 2024
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Articles published in this journal are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under this license:
- Share: Copy and redistribute the material in any medium or format
- Adapt: Remix, transform, and build upon the material for any purpose, including commercially
Attribution required: You must give appropriate credit, provide a link to the license, and indicate if changes were made.
License URL: https://creativecommons.org/licenses/by/4.0/
Authors retain copyright of their work while granting the journal first publication rights.
